Amazon is deepening its push into high-demand GLP-1 drugs by adding Novo Nordisk’s Ozempic pill to Amazon Pharmacy, pairing kiosk pickup with same-day delivery across roughly 3,000 US cities and towns.
The move gives Amazon a bigger role in diabetes drug distribution after earlier expanding access to Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo, two GLP-1 treatments tied to the broader obesity and metabolic health market. Amazon has delivered GLP-1 medications since 2021, but pill formats create a simpler logistics path because they do not require the cold-chain handling needed for injectables.
Amazon said Ozempic will be available through same-day delivery in nearly 3,000 locations, with plans to expand the footprint to about 4,500 cities and towns by year-end. The company says roughly half of its US customers already have access to same-day medication delivery, while all customers can receive medications within four days.
Sponsored · Selkirk Copper Mines
Customers with a prescription can order the Ozempic pill through Amazon Pharmacy for $149 per month on a cash-pay basis, while insured customers may pay as little as $25.
The company has already used select California kiosks for Novo Nordisk’s Wegovy pill, and the Ozempic pill is expected to follow the same access model.
Amazon does not require a One Medical subscription to use the kiosks, according to prior reporting on its GLP-1 kiosk expansion. One Medical memberships can add primary care access, but the pharmacy pickup model itself is designed around reducing wait times, delivery fees, and traditional retail pharmacy friction.
Amazon’s addition of Ozempic follows a rapid buildout of its GLP-1 catalog. The company began stocking Novo Nordisk’s Wegovy pill in January, then added Eli Lilly’s Foundayo pill in April before moving to the Ozempic pill in May.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
